{"id":25222,"date":"2026-07-29T10:38:56","date_gmt":"2026-07-29T10:38:56","guid":{"rendered":"https:\/\/thestrategystory.com\/blog\/?p=25222"},"modified":"2026-07-29T10:49:41","modified_gmt":"2026-07-29T10:49:41","slug":"sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money","status":"publish","type":"post","link":"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/","title":{"rendered":"Sun Pharma Business Model in 2026: How Sun Pharmaceutical Makes Money"},"content":{"rendered":"\n

Sun Pharmaceutical Industries Limited (Sun Pharma) has evolved from a domestic generic drug manufacturer into one of the world’s leading specialty pharmaceutical companies. Today, the company operates across more than 100 countries<\/strong>, serving millions of patients through a diversified portfolio of specialty medicines, branded generics, generic formulations, consumer healthcare products, and Active Pharmaceutical Ingredients (APIs). Supported by 40 manufacturing facilities<\/strong>, 6 global R&D centres<\/strong>, and over 43,000 employees<\/strong>, Sun Pharma has built one of the most extensive pharmaceutical networks in the industry.<\/p>\n\n\n\n

Unlike traditional pharmaceutical companies that rely on either patented medicines or low-cost generics, Sun Pharma has adopted a balanced business model combining innovation with affordability. The company continues to expand its high-margin specialty portfolio while maintaining leadership in branded generics, particularly in India and emerging markets. This diversified approach reduces dependence on any single product, geography, or therapeutic category while creating multiple long-term growth engines.<\/p>\n\n\n\n

FY2024-25 marked another strong year for the company. Sun Pharma reported revenue from operations of Rs. 52,578 crore<\/strong>, net profit of Rs. 10,929 crore<\/strong>, and invested Rs. 3,248 crore<\/strong> in research and development, representing 6.2% of total sales<\/strong>. The company also strengthened its Specialty business through new product approvals, strategic acquisitions, and licensing agreements while continuing to expand its presence across India, the US, and emerging markets.<\/p>\n\n\n\n

Rather than competing purely on price, Sun Pharma’s strategy increasingly focuses on differentiated therapies, scientific innovation, global commercial capabilities, and operational excellence. This combination has enabled the company to become India’s largest pharmaceutical company while steadily increasing its presence in global specialty medicines.<\/p>\n\n\n\n

Sun Pharma Business Strategy in 2026<\/a><\/p>\n\n\n\n

Industry Problems Sun Pharma Solves<\/h2>\n\n\n\n

The global healthcare industry faces several structural challenges, including rising chronic diseases, ageing populations, increasing healthcare costs, limited access to innovative therapies, and significant disparities in medicine availability across developed and emerging markets. At the same time, governments and healthcare providers are under constant pressure to improve patient outcomes while keeping healthcare affordable.<\/p>\n\n\n\n

One major challenge is balancing innovation with affordability<\/strong>. While breakthrough therapies continue to improve treatment outcomes, many remain prohibitively expensive for patients and healthcare systems. Simultaneously, generic drug manufacturers face intense pricing pressure, making it difficult to sustain profitability while maintaining high quality standards. Sun Pharma addresses this challenge by combining innovative specialty medicines with a broad portfolio of affordable generic and branded generic products, allowing it to serve diverse patient populations across different income levels.<\/p>\n\n\n\n

Another industry challenge is the growing burden of chronic and complex diseases such as psoriasis, alopecia areata, oncology, ophthalmology, diabetes, cardiovascular disorders, and autoimmune diseases. These conditions require long-term treatment, continuous innovation, and specialised medicines. Sun Pharma has increasingly focused its investments on specialty therapies targeting high unmet medical needs while continuing to support patients with affordable medicines across acute and chronic therapeutic categories.<\/p>\n\n\n\n

The pharmaceutical industry also operates in one of the world’s most heavily regulated environments. Companies must comply with varying regulatory standards across countries while ensuring uninterrupted product quality, supply chain resilience, and manufacturing compliance. With operations spanning more than 100 countries, Sun Pharma has built extensive regulatory, manufacturing, and quality systems that enable it to serve diverse global markets while adapting to changing regulatory requirements.<\/p>\n\n\n\n

Finally, healthcare access remains uneven across the world. Many emerging markets continue to face affordability constraints, limited healthcare infrastructure, and inadequate access to advanced therapies. Through its extensive portfolio of branded generics, generics, APIs, consumer healthcare products, and global commercial network, Sun Pharma helps improve medicine accessibility while expanding healthcare reach across both developed and developing markets.<\/p>\n\n\n\n

Sun Pharma SWOT Analysis in 2026<\/a><\/p>\n\n\n\n

Business Model<\/h2>\n\n\n\n

Sun Pharma operates a diversified pharmaceutical business model<\/strong> that combines innovation-driven specialty medicines with large-scale generic manufacturing, branded generics, consumer healthcare products, and Active Pharmaceutical Ingredients (APIs). Unlike pharmaceutical companies that depend entirely on patented drugs or low-cost generics, Sun Pharma has deliberately built a balanced portfolio that enables it to generate stable cash flows while investing in future innovation. This diversification also reduces dependence on any single geography, product, or therapeutic area.<\/p>\n\n\n\n

The company’s fastest-growing business is its Global Specialty<\/strong> segment. This business focuses on innovative, patent-protected therapies targeting areas with high unmet medical needs, including dermatology, ophthalmology, onco-dermatology, immunology, and rare diseases. During FY2024-25, Specialty contributed 20% of consolidated revenue<\/strong>, up from 18% in the previous year. The portfolio includes products such as ILUMYA<\/strong>, WINLEVI<\/strong>, CEQUA<\/strong>, ODOMZO<\/strong>, LEQSELVI<\/strong>, and UNLOXCYT<\/strong>, while the company continues expanding its pipeline through acquisitions and licensing agreements.<\/p>\n\n\n\n

Alongside innovation, Sun Pharma remains one of the world’s leading manufacturers of generic and branded generic medicines<\/strong>. The company markets thousands of products across acute and chronic therapies in dosage forms including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. In India and many emerging markets, branded generics remain a key competitive advantage because physicians prescribe medicines by brand rather than generic molecule, allowing Sun Pharma to build strong brand recognition and long-term customer relationships.<\/p>\n\n\n\n

Another important component of the business model is consumer healthcare<\/strong>. The company markets a broad portfolio of over-the-counter (OTC) products covering cough and cold, digestive care, vitamins, pain relief, sore throat treatments, and lifestyle healthcare products. This business benefits from increasing consumer awareness, preventive healthcare, self-medication trends, and expanding retail pharmacy networks.<\/p>\n\n\n\n

Sun Pharma also operates a significant Active Pharmaceutical Ingredients (API)<\/strong> business, supplying pharmaceutical ingredients used in both internal manufacturing and external customers. Its API portfolio includes oncology, peptides, steroids, hormones, and controlled substances. Vertical integration through API manufacturing enhances supply chain security, improves cost competitiveness, and provides greater control over product quality while reducing dependence on third-party suppliers.<\/p>\n\n\n\n

Supporting these businesses is a strong research and manufacturing ecosystem. The company operates 40 manufacturing facilities across six continents<\/strong>, 6 global R&D centres<\/strong>, and employs approximately 2,900 R&D professionals<\/strong>. Every year, Sun Pharma invests 6\u20138% of its global revenue<\/strong> into research and development, focusing on differentiated formulations, complex generics, specialty medicines, and clinical development. This scientific capability enables the company to continuously replenish its product pipeline while strengthening long-term competitiveness.<\/p>\n\n\n\n

Sun Pharma PESTEL Analysis in 2026<\/a><\/p>\n\n\n\n

How Sun Pharma Makes Money<\/h2>\n\n\n\n

Sun Pharma generates revenue through five major business segments spread across multiple global markets. The largest contributor is the India business<\/strong>, which accounted for 33% of FY2024-25 revenue<\/strong>. As India’s largest pharmaceutical company by market share, Sun Pharma sells branded formulations across multiple therapeutic areas through one of the country’s largest physician engagement and field sales networks. During FY2024-25, the company launched 42 new products<\/strong> in India while further expanding its presence across Tier II and Tier III cities.<\/p>\n\n\n\n

The United States<\/strong> represents another major revenue source, contributing approximately 31% of consolidated revenue<\/strong>. Unlike India, where branded generics dominate, Sun Pharma’s US business is increasingly driven by high-margin Specialty medicines alongside generic formulations. Products such as ILUMYA, WINLEVI, CEQUA, and ODOMZO continue to strengthen the company’s position in dermatology, ophthalmology, and specialty therapeutics.<\/p>\n\n\n\n

The company also earns substantial revenue from Emerging Markets<\/strong>, which contributed around 18% of FY2024-25 revenue<\/strong>, and Rest of the World (RoW)<\/strong> markets, contributing another 14%<\/strong>. These regions provide geographical diversification while benefiting from growing healthcare spending, rising chronic diseases, expanding insurance coverage, and increasing access to affordable medicines.<\/p>\n\n\n\n

Another important revenue stream comes from Active Pharmaceutical Ingredients (APIs)<\/strong> and related businesses, which contributed approximately 4% of revenue<\/strong>. In addition to supplying its own manufacturing operations, Sun Pharma sells APIs externally to pharmaceutical manufacturers worldwide, creating an additional source of income while leveraging manufacturing scale.<\/p>\n\n\n\n

Innovation has become an increasingly important driver of future earnings. During FY2024-25, Sun Pharma strengthened its specialty pipeline through the acquisition of Checkpoint Therapeutics<\/strong>, bringing UNLOXCYT<\/strong>, the first FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, into its portfolio. The company also signed a global licensing agreement with Philogen<\/strong> for the anti-cancer immunotherapy Fibromun<\/strong> and received FDA approval for LEQSELVI<\/strong>, a treatment for severe alopecia areata. These investments are expected to generate higher-margin revenues over the long term.<\/p>\n\n\n\n

Future Outlook<\/h2>\n\n\n\n

Sun Pharma’s long-term strategy is centred on becoming a leading global specialty pharmaceutical company while maintaining its leadership in branded generics and affordable medicines. Management expects the Specialty business to remain its fastest-growing segment and plans to continue investing 6\u20138% of annual sales<\/strong> into research and development, with a growing proportion allocated to innovative therapies.<\/p>\n\n\n\n

The company also plans to strengthen manufacturing compliance, accelerate upcoming product launches such as LEQSELVI<\/strong> and UNLOXCYT<\/strong>, expand its Specialty pipeline, enhance supply chain resilience, increase digital transformation, and integrate sustainability across its operations. Supported by a net cash position of approximately US$3.1 billion<\/strong>, strong global manufacturing capabilities, diversified revenue streams, and an expanding innovation pipeline, Sun Pharma appears well positioned to strengthen its leadership in both specialty pharmaceuticals and global generic medicines while continuing to improve patient access to healthcare worldwide.<\/p>\n\n\n\n

Source: Sun Pharma Annual Report 2024-25<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Explore Sun Pharma’s business model in 2026. Learn how India’s largest pharmaceutical company generates revenue through specialty medicines, generics, APIs, consumer healthcare, and global operations.<\/p>\n","protected":false},"author":1,"featured_media":25207,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[166],"tags":[],"class_list":{"0":"post-25222","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business-model"},"yoast_head":"\nSun Pharma Business Model in 2026: How Sun Pharmaceutical Makes Money - The Strategy Story<\/title>\n<meta name=\"description\" content=\"Explore Sun Pharma's business model in 2026. Learn how India's largest pharmaceutical company generates revenue through specialty medicines, generics, APIs, consumer healthcare, and global operations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sun Pharma Business Model in 2026: How Sun Pharmaceutical Makes Money - The Strategy Story\" \/>\n<meta property=\"og:description\" content=\"Explore Sun Pharma's business model in 2026. Learn how India's largest pharmaceutical company generates revenue through specialty medicines, generics, APIs, consumer healthcare, and global operations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/\" \/>\n<meta property=\"og:site_name\" content=\"The Strategy Story\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T10:38:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-29T10:49:41+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/thestrategystory.com\/blog\/wp-content\/uploads\/2026\/07\/glsun-mall-WNX6uk-1LV4-unsplash.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"427\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/\",\"url\":\"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/\",\"name\":\"Sun Pharma Business Model in 2026: How Sun Pharmaceutical Makes Money - The Strategy Story\",\"isPartOf\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/#website\"},\"datePublished\":\"2026-07-29T10:38:56+00:00\",\"dateModified\":\"2026-07-29T10:49:41+00:00\",\"author\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972\"},\"description\":\"Explore Sun Pharma's business model in 2026. Learn how India's largest pharmaceutical company generates revenue through specialty medicines, generics, APIs, consumer healthcare, and global operations.\",\"breadcrumb\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/thestrategystory.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sun Pharma Business Model in 2026: How Sun Pharmaceutical Makes Money\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#website\",\"url\":\"https:\/\/thestrategystory.com\/blog\/\",\"name\":\"The Strategy Story\",\"description\":\"Simplifying Business Strategies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/thestrategystory.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\/\/thestrategystory.com\/blog\"],\"url\":\"https:\/\/thestrategystory.com\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sun Pharma Business Model in 2026: How Sun Pharmaceutical Makes Money - The Strategy Story","description":"Explore Sun Pharma's business model in 2026. Learn how India's largest pharmaceutical company generates revenue through specialty medicines, generics, APIs, consumer healthcare, and global operations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/","og_locale":"en_US","og_type":"article","og_title":"Sun Pharma Business Model in 2026: How Sun Pharmaceutical Makes Money - The Strategy Story","og_description":"Explore Sun Pharma's business model in 2026. Learn how India's largest pharmaceutical company generates revenue through specialty medicines, generics, APIs, consumer healthcare, and global operations.","og_url":"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/","og_site_name":"The Strategy Story","article_published_time":"2026-07-29T10:38:56+00:00","article_modified_time":"2026-07-29T10:49:41+00:00","og_image":[{"width":640,"height":427,"url":"http:\/\/thestrategystory.com\/blog\/wp-content\/uploads\/2026\/07\/glsun-mall-WNX6uk-1LV4-unsplash.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/","url":"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/","name":"Sun Pharma Business Model in 2026: How Sun Pharmaceutical Makes Money - The Strategy Story","isPartOf":{"@id":"https:\/\/thestrategystory.com\/blog\/#website"},"datePublished":"2026-07-29T10:38:56+00:00","dateModified":"2026-07-29T10:49:41+00:00","author":{"@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972"},"description":"Explore Sun Pharma's business model in 2026. Learn how India's largest pharmaceutical company generates revenue through specialty medicines, generics, APIs, consumer healthcare, and global operations.","breadcrumb":{"@id":"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/thestrategystory.com\/blog\/sun-pharma-business-model-in-2026-how-sun-pharmaceutical-makes-money\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thestrategystory.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Sun Pharma Business Model in 2026: How Sun Pharmaceutical Makes Money"}]},{"@type":"WebSite","@id":"https:\/\/thestrategystory.com\/blog\/#website","url":"https:\/\/thestrategystory.com\/blog\/","name":"The Strategy Story","description":"Simplifying Business Strategies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thestrategystory.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/thestrategystory.com\/blog"],"url":"https:\/\/thestrategystory.com\/blog\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/25222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/comments?post=25222"}],"version-history":[{"count":2,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/25222\/revisions"}],"predecessor-version":[{"id":25234,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/25222\/revisions\/25234"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/media\/25207"}],"wp:attachment":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/media?parent=25222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/categories?post=25222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/tags?post=25222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}